← Eichor
Study identifier: NCT05365672 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation

Condition: Kidney Transplantation  ·  Sponsor: TolerogenixX GmbH

PhasePhase 2
Planned participants126
Who can joinAll sexes, 18 Years to 69 Years
Healthy volunteersNo

About this study

In this clinical trial the investigational medicinal product MIC is to be examined for its efficacy and safety in patients with living kidney transplantation. For this purpose the patients participating in the clinical trial and their associated kidney donors are randomly assigned to one of three treatment groups during the screening procedure. For the production of the investigational medicinal product MIC for the patients in the MIC therapy group mononuclear cells of the peripheral blood are obtained from the donors in a leukapheresis procedure. In the subsequent treatment phase, the patients in the MIC therapy group receive MIC as a weight-adjusted single dose administered intravenously. As part of the 12-month follow-up phase the kidney transplant and the corresponding immunosuppressive therapy will take place seven days later. Patients in the control group will receive a conventional standard immunosuppressive regimen without prior administration of the investigational medicinal product MIC after kidney transplantation. All patients taking part in this clinical trial are followed up for one year after kidney transplantation with regard to the efficacy and safety of MIC in regular visits at their study site. As the investigational medicinal product is an advanced therapy medicinal product (ATMP) all subjects will be monitored for a further 2 years after the end of the follow-up phase of the clinical trial. A total of 63 transplant pairs, consisting of donor and transplan…

This description comes directly from the study's public registry record.

Talk to the study team

Matthias Schaier, Prof.Dr.med.  ·  +49 162 2638 005  ·  schaier@tolerogenixx.com

Always discuss trial participation with your own doctor first.

Locations (8)

Medizinische Klinik mit Schwerpunkt Nephrologie und Internistische Intensivmedizin Charité - Universitätsmedizin BerlinBerlin, GermanyNot Yet Recruiting
Universitätsklinikum Hamburg-Eppendorf, Universitäres Transplantations CentrumHamburg, GermanyRecruiting
Innere Medizin V; Klinik für Hämatologie, Onkologie, Rheumatologie; Universitätsklinikum HeidelbergHeidelberg, GermanyRecruiting
Medizinische Klinik, Innere Medizin X Nephrologie - Nierenzentrum Universitätsklinikum HeidelbergHeidelberg, GermanyRecruiting
Transplantationszentrum München; Ludwig-Maximilians-UniversitätMunich, GermanyRecruiting
Klinikum rechts der Isar, Abteilung Nephrologie, Technische Universität MünchenMunich, GermanyNot Yet Recruiting
Universitätsklinikum Münster, TransplantationsnephrologieMünster, GermanyRecruiting
Klinik für Nieren-, Hochdruck- und Autoimmunerkrankungen; Transplantationszentrum StuttgartStuttgart, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05365672